Articles Archives | Page 120 of 128 | Sterne Kessler

Ten Takeaways From the FDA’s December 2016 Revisions to its Hatch-Waxman Regulations

Summary of Proposed and Final Notable Changes to 37 CFR 2, 6, and 7 (Trademarks)

Strengthening Pending and Future Application Portfolios in Advance of Potential Attack in AIA Proceedings

Strategic Planning: It’s not just for ‘BigLaw’ anymore

Some Declaratory Judgment Guidance for ANDA Litigants

Sandoz Decision Increases Importance of Post-Grant Proceedings to Biosimilar Developers

RPI or RIP? How failing to list a real-party-in-interest can kill a post-grant proceeding

Public Disclosure Grace Periods And The Trans-Pacific Partnership: Member States Seek Harmonization with the America Invents Act

Protecting Your Ideas

Proceed With Caution